It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar.
We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.
It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar.
Expert: Chris Wasden, Head of DTx , Happify Health
Chris leads Happify's digital therapeutics effort to take its world-leading digital mental health and wellbeing platform to the pharmaceutical and healthcare industry. He also serves as a board member for the Digital Therapeutics Alliance. Connect with Chris to get his perspective on how digital therapeutics are shaping the future of mental health and psychiatric care. https://www.linkedin.com/in/chriswasden/
Snapshot of the story
This month, digital therapeutics (DTx) company Happify Health announced their first prescription DTx to treat patients with both major depressive disorder (MDD) and generalized anxiety disorder (GAD). The therapy, dubbed Ensemble, includes a 10-week cognitive behavioral therapy (CBT) program to help teach patients how to change negative thought patterns. It also includes a dashboard doctors can use to monitor patients. It is the first transdiagnostic PDT for MDD and GAD available in the U.S.
Why is it notable:
Industry Implications:
Read the full story here.
We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.
Expert: Paul Feldheausen, Director Of Strategic Partnerships, Holmusk
Paul is the Director of Growth Operations & Partnerships at Holmusk, where he is working to build the world's largest real-world evidence platform for behavioral health and chronic diseases. He has extensive expertise in leading complex health engagements in the US and Asia, and over the past 15 years Paul has worked to drive behavioral and structural changes in the way patients interact and participate within the health ecosystems. Connect with Paul to get his perspective on leveraging real-world data for improving outcomes.
https://www.linkedin.com/in/paul-feldhausen/
Snapshot of the story
This week Otsuka announced the signing of a three-year collaboration with global data science company Holmusk to enhance digital health and data analytics for global behavioral health programs. One of Holmusk’s main focuses is on building a real-world evidence (RWE) platform for behavioral health. Together, Otsuka and Holmusk will work to drive a deeper understanding of unmet patient needs and real-world outcomes by employing proprietary analytics and artificial intelligence (AI) on multiple real-world data sources.
Why it is notable
Industry Implications
Read the full story here.
We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.
Expert: Murray Brozinskly, Conversa Health
Murray is a creative entrepreneur who has started, run, and served as a senior executive at numerous companies. He has extensive experience in leadership, strategy, bringing new products to market, generating revenue, building strategic relationships, as well as M&A. In addition to working as a digital health leader in automated care management at Conversa Health he works as a Board member and advisor to other promising technology start-ups in various industries. Connect with Murray to get his perspective on how M&As will shape the strategy of telemedicine companies in the future. https://www.linkedin.com/in/murraybrozinsky/
Snapshot of the story
This week telehealth giant Amwell announced the acquisition of SilverCloud Health and Conversa Health in a bid to enhance its virtual care platform. Their acquisition will broaden Amwells offersings differentiating it among competitors. We are super proud of our friends at Conversa Health & Silvercloud Health on this milestone!'. Covid-19 has cut through the red tape that initially restricted telehealth adoption, forcing the healthcare world to do a 180° on digital health, and these acquisitions offer a clear example to how telehealth is innovatively responding.
Why is it notable:
Industry Implications
Read the full story here.
Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.
The regulatory landscape for any medical device can be difficult to navigate. Join this Masterclass to learn more about this topic and discuss with experts in this field.
Digital therapeutics (DTx) are yet to show success at scale with traditional salesforce distribution channels. Apply now to discuss this further with your peers working in this space.
Are your Digital Health innovations being slowed or even derailed by regulatory, security, privacy or legal compliance considerations? Apply now to join HealthXL in this expert led Masterclass to deep dive into this topic.
In the face of macroeconomic challenges and a tightening financial landscape, DTx startups are experiencing an intensified competition for investment. Join HealthXl in this peer led discussion to deep dive into this topic. Seats are limited so apply now to secure your place.
Are you a HealthXL Member? See the Full Report Here
Non-HealthXL Member? You can purchase the report HERE
Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.
The regulatory landscape for any medical device can be difficult to navigate. Join this Masterclass to learn more about this topic and discuss with experts in this field.
The benefits of digital technologies in oncology are undeniable; however, effectively demonstrating their value to end users is pivotal for the success of these products. Apply now to join your peers in this interactive discussion. Spaces are limited so apply now to secure your seat.
Digital health care pathways in immunology can become siloed due to the fragmentation of healthcare services and the lack of interoperability among healthcare systems and providers. Apply now to join this session and deep dive into this topic with your peers working in this space.
Remote patient monitoring (RPM) technologies can benefit the entire surgical workflow, by allowing preoperative and postoperative monitoring that improves patient experience and reduces the overall cost of care. Apply now to secure your place as we deep dive into this topic.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.